Literature DB >> 2213118

Temporal lobe ganglioglioma in refractory epilepsy: CT and MR in three cases.

M C Chamberlain1, G A Press.   

Abstract

Three patients (ages 5, 16 and 21 years) with chronic, refractory, partial epilepsy and temporal lobe ganglioglioma were evaluated for surgical treatment. Noncontrast CT revealed a low attenuation, cystic temporal lesion in 2 patients. One neoplasm demonstrated focal calcification and temporal altrophy, while the other had mass effect and surrounding edema. Contrast enhancement of the mass was seen in one instance. Non-contrast and post-contrast CT were completely normal in the remaining patient. MR was abnormal in both patients in which it was performed (including the patient with a normal CT examination). Lesions were hyperintense on T2W inmages and iso-to-hypointense on T1W images when compared to normal parenchyma. Regions of calcification were missed on standard spin-echo sequences. Continuous video EEG monitoring captured habitual partial seizures in all patients; focal onset correlated with tumor location in each instance. Intraoperative electrocorticography corroborated the EEG results. Two of three patients underwent gross total resection. Pathologic features were characteristic of ganglioglioma in all instances. All patients have been seizure-free postoperatively [mean follow-up: 16 months (range 13-18 months)] and without evidence of tumor recurrence. Although ganglioglioma is an unusual cause of refractory temporal lobe epilepsy, our short term follow-up suggests excellent outcome with both partial and gross total resection.

Entities:  

Mesh:

Year:  1990        PMID: 2213118     DOI: 10.1007/bf00167073

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

1.  Magnetic resonance imaging (1.5 tesla) in patients with intractable focal seizures.

Authors:  R P Lesser; M T Modic; M A Weinstein; P M Duchesneau; H Lüders; D S Dinner; H H Morris; M Estes; S M Chou; J F Hahn
Journal:  Arch Neurol       Date:  1986-04

2.  Computed tomography of intracerebral gangliogliomas.

Authors:  R A Zimmerman; L T Bilaniuk
Journal:  J Comput Tomogr       Date:  1979-03

3.  Pathologic aspects of epilepsy with special reference to the surgical pathology of focal cerebral seizures.

Authors:  G Mathieson
Journal:  Adv Neurol       Date:  1975

4.  Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas.

Authors:  M C Chamberlain; J A Murovic; V A Levin
Journal:  Neurology       Date:  1988-09       Impact factor: 9.910

5.  Temporal lobe gangliogliomas in children.

Authors:  E Ventureyra; S Herder; B K Mallya; D Keene
Journal:  Childs Nerv Syst       Date:  1986       Impact factor: 1.475

6.  Gangliogliomas in children. A clinicopathological study.

Authors:  E Garrido; L F Becker; H J Hoffman; E B Hendrick; R Humphreys
Journal:  Childs Brain       Date:  1978

7.  Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy.

Authors: 
Journal:  Epilepsia       Date:  1981-08       Impact factor: 5.864

8.  Temporal lobectomy in children with epilepsy.

Authors:  F B Meyer; W R Marsh; E R Laws; F W Sharbrough
Journal:  J Neurosurg       Date:  1986-03       Impact factor: 5.115

9.  Intracerebral ganglioglioma.

Authors:  B Demierre; F A Stichnoth; A Hori; O Spoerri
Journal:  J Neurosurg       Date:  1986-08       Impact factor: 5.115

10.  Ganglioglioma: a correlative clinicopathological and radiological study of ten surgically treated cases with follow-up.

Authors:  U P Kalyan-Raman; W C Olivero
Journal:  Neurosurgery       Date:  1987-03       Impact factor: 4.654

View more
  1 in total

Review 1.  Gangliogliomas: a clinicopathological study of 25 cases and review of the literature.

Authors:  H G Krouwer; R L Davis; M W McDermott; T Hoshino; M D Prados
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.